Avalo Therapeutics (AVTX) Revenue & Revenue Breakdown
Avalo Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.41M
Main Segment (Y)
Product
Avalo Therapeutics Revenue by Period
Avalo Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.41M | -92.20% |
| 2022-12-31 | $18.05M | 234.40% |
| 2021-12-31 | $5.40M | -19.42% |
| 2020-12-31 | $6.70M | -0.76% |
| 2019-12-31 | $6.75M | -63.17% |
| 2018-12-31 | $18.33M | -34.11% |
| 2017-12-31 | $27.81M | 2312.24% |
| 2016-12-31 | $1.15M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Avalo Therapeutics generated $1.41M in revenue during NA 2023, up -92.20% compared to the previous quarter, and up 7.68% compared to the same period a year ago.
Avalo Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $571.00K | 141.95% |
| 2023-09-30 | $236.00K | -63.30% |
| 2023-06-30 | $643.00K | 35.37% |
| 2023-03-31 | $475.00K | -46.99% |
| 2022-12-31 | $896.00K | -94.01% |
| 2022-09-30 | $14.95M | 1347.14% |
| 2022-06-30 | $1.03M | -11.94% |
| 2022-03-31 | $1.17M | 435.62% |
| 2021-12-31 | $219.00K | -83.78% |
| 2021-09-30 | $1.35M | -59.76% |
| 2021-06-30 | $3.35M | 609.30% |
| 2021-03-31 | $473.00K | -68.39% |
| 2020-12-31 | $1.50M | 34.70% |
| 2020-09-30 | $1.11M | -16.97% |
| 2020-06-30 | $1.34M | -51.42% |
| 2020-03-31 | $2.75M | -131.57% |
| 2019-12-31 | $-8.72M | -255.41% |
| 2019-09-30 | $5.61M | 26.16% |
| 2019-06-30 | $4.45M | -17.78% |
| 2019-03-31 | $5.41M | 8.57% |
| 2018-12-31 | $4.98M | 22.32% |
| 2018-09-30 | $4.07M | -14.84% |
| 2018-06-30 | $4.79M | 6.74% |
| 2018-03-31 | $4.48M | 100.70% |
| 2017-12-31 | $2.23M | -91.08% |
| 2017-09-30 | $25.04M | 15766.66% |
| 2017-06-30 | $157.80K | -58.93% |
| 2017-03-31 | $384.21K | 111.10% |
| 2016-12-31 | $182.00K | -43.39% |
| 2016-09-30 | $321.50K | -50.58% |
| 2016-06-30 | $650.49K | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Avalo Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Avalo Therapeutics Revenue Breakdown
Avalo Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License | $516.00K | $14.69M | $625.00K | - | $100.00K |
| Product | $1.41M | $3.36M | $4.77M | $6.70M | - |
| Sales Force Revenue | - | - | - | - | - |
| Sales Revenue, Product | - | - | - | - | $6.65M |
| Prescription Drugs | - | - | - | - | $6.65M |
Avalo Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (73.18%), and License (26.82%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $54.00K | $236.00K | $643.00K | $475.00K | $726.00K | $432.00K | $1.03M | $1.17M | $219.00K | $1.35M | $2.73M | $473.00K | $1.50M | $1.11M | - | - | - | - | - | - |
| License | - | - | $170.00K | $14.52M | - | - | - | $625.00K | - | $100.00K | - | - | - | - | - | - | - | - | - | - |
| Prescription Drugs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.19M | $2.65M | $3.62M | $2.91M | $1.98M | $2.79M |
| Prescribed Dietary Supplements | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.32M | $1.80M | $1.79M | $1.91M | $2.10M | $1.93M |
| Sales Force Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $159.18K | - | $74.22K |
| Sales Revenue, Product | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.51M | $4.45M | $5.41M | $4.82M | $4.07M | - |
| Grant Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avalo Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Product (100.00%).
Avalo Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ACLX | Arcellx | $110.32M | $27.38M |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| AVTX | Avalo Therapeutics | $1.41M | - |
| BNTC | Benitec Biopharma | $75.00K | $6.00K |
| BNOX | Bionomics | $22.05K | $98.94K |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| ALXO | ALX Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| ALZN | Alzamend Neuro | - | - |
| EWTX | Edgewise Therapeutics | - | - |
AVTX Revenue FAQ
What is Avalo Therapeutics’s yearly revenue?
Avalo Therapeutics's yearly revenue for 2023 was $1.41M, representing a decrease of -92.20% compared to 2022. The company's yearly revenue for 2022 was $18.05M, representing an increase of 234.40% compared to 2021. AVTX's yearly revenue for 2021 was $5.4M, representing a decrease of -19.42% compared to 2020.
What is Avalo Therapeutics’s quarterly revenue?
Avalo Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). AVTX's quarterly revenue for Q4 2023 was $571K, a 141.95% increase from the previous quarter (Q3 2023), and a -36.27% decrease year-over-year (Q4 2022).
What is Avalo Therapeutics’s revenue growth rate?
Avalo Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -73.92%, and for the last 5 years (2019-2023) was -79.14%.
What are Avalo Therapeutics’s revenue streams?
Avalo Therapeutics's revenue streams in c 23 are License, and Product. License generated $516K in revenue, accounting 26.82% of the company's total revenue, down -96.49% year-over-year. Product generated $1.41M in revenue, accounting 73.18% of the company's total revenue, down -58.15% year-over-year.
What is Avalo Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Avalo Therapeutics was Product. This segment made a revenue of $1.41M, representing 73.18% of the company's total revenue.